Your browser doesn't support javascript.
loading
Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician-pharmacist clinic.
Sweiss, Karen; Calip, Gregory S; Wirth, Scott; Rondelli, Damiano; Patel, Pritesh.
Afiliación
  • Sweiss K; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
  • Calip GS; Cancer Center, University of Illinois, Chicago, IL, USA.
  • Wirth S; Cancer Center, University of Illinois, Chicago, IL, USA.
  • Rondelli D; Center for Pharmacoepidemiology and Pharmacoeconomic Research, Chicago IL, USA.
  • Patel P; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
J Oncol Pharm Pract ; 26(3): 536-542, 2020 Apr.
Article en En | MEDLINE | ID: mdl-31189419
ABSTRACT

OBJECTIVE:

To compare polypharmacy and potentially inappropriate medication use in multiple myeloma patients receiving care under a traditional, physician-managed, or collaborative physician-pharmacist clinic.

DESIGN:

Retrospective chart review.

SETTING:

Urban academic cancer center. DATA SOURCE Computerized electronic record. PATIENTS Forty-four patients in the traditional physician-managed clinic and 57 patients in the collaborative physician-pharmacist clinic. MEASUREMENTS AND MAIN

RESULTS:

Patients in the collaborative clinic took fewer medications on average (9 vs. 7, p = 0.045). Although the median number of myeloma-related medications was higher (2 vs. 4, p < 0.0001), the number of non-myeloma-related medications was lower (7 vs. 3, p < 0.0001) in the collaborative clinic. Polypharmacy rates were high in both clinics (93% vs. 84%, p = 0.22). However, the collaborative clinic had a lower rate of polypharmacy of non-myeloma medications (71 vs. 33%, p = 0.0003), including both minor (five to nine medications, 48 vs. 28%, p = 0.06) and major (≥10 medications, 23 vs. 5%, p = 0.02) polypharmacy. Minor polypharmacy of myeloma-related medications was higher in the collaborative clinic (32 vs. 2%; p = 0.0002). Multivariate analysis showed a reduced risk of having a higher number of medications (Relative risk (RR) 0.79, 95% confidence interval 0.67-0.93; p = 0.004), a lower risk of having any polypharmacy of non-myeloma-related medications (RR 0.41, 95% confidence interval 0.25-0.67; p < 0.001) and a lower risk of receiving potentially inappropriate medication (RR 0.62, 95% confidence interval 0.41-0.95; p = 0.029) in the collaborative clinic.

CONCLUSIONS:

Multiple myeloma patients have a high rate of polypharmacy but comanagement with a pharmacist reduced the number of all medications, but in particular the number of non-myeloma-related medications.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Polifarmacia / Lista de Medicamentos Potencialmente Inapropiados / Mieloma Múltiple Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Polifarmacia / Lista de Medicamentos Potencialmente Inapropiados / Mieloma Múltiple Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos